The role of chronic inflammation in the development of gastrointestinal cancers: Reviewing cancer prevention with natural antiinflammatory intervention

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 1, 2016, Pages 129-139

  Lee, Ho Jae ^a   Park, Jong Min ^b   Han, Young Min ^b   Gil, Hong Kwon ^b   Kim, Jinhyung ^b   Chang, Ji Young ^b   Jeong, Migyeong ^b   Go, Eun Jin ^b   Hahm, Ki Baik ^b  

^a Gachon University   (South Korea)

^b CHA University   (South Korea)

Author keywords

Cancer prevention; GI cancer; GI inflammation; Oxidative stress; TGF ; TNF

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 18; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; LYMPHOTOXIN; TUMOR NECROSIS FACTOR;

ANTIINFLAMMATORY ACTIVITY; CANCER PREVENTION; CARCINOGENESIS; CHRONIC GASTRITIS; CHRONIC INFLAMMATION; COLITIS; DIGESTIVE SYSTEM CANCER; DISEASE PREDISPOSITION; ESOPHAGUS CANCER; GASTROENTEROLOGY; GASTROESOPHAGEAL REFLUX; HUMAN; MEDICINAL PLANT; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; TUMOR MICROENVIRONMENT; CHRONIC DISEASE; COMPLICATION; DIGESTIVE SYSTEM NEOPLASMS; ESOPHAGITIS; GASTRITIS; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; METABOLISM; SCLEROSING CHOLANGITIS;

ANTI-INFLAMMATORY AGENTS; CHOLANGITIS, SCLEROSING; CHRONIC DISEASE; DIGESTIVE SYSTEM NEOPLASMS; ESOPHAGITIS; GASTRITIS; HUMANS; INFLAMMASOMES; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; LYMPHOTOXIN-ALPHA; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84946434090     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2016.1103179     Document Type: Review

References (80)

1. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet. 2001;357(9255):539-545.
2. Haddow A. Molecular repair, wound healing, and carcinogenesis: Tumor production a possible overhealing? Adv Cancer Res. 1972;16:181-234.
3. Dvorak HF. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315(26):1650-1659.
4. Schafer M, Werner S. Cancer as an overhealing wound: An old hypothesis revisited. Nat Rev Mol Cell Biol. 2008;9 (8):628-638.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646-674.
6. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436-444.
7. Shaheen NJ. Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 2005;128(6):1554-1566.
8. Kapoor H, Agrawal DK, Mittal SK. Barrett's esophagus: Recent insights into pathogenesis and cellular ontogeny. Transl Res J Lab Clin Med. 2015;166 (1):28-40.
9. Colleypriest BJ, Ward SG, Tosh D. How does inflammation cause Barrett's metaplasia? Curr Opin Pharmacol. 2009;9 (6):721-726.
10. Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: The ABCs of making Barrett's metaplasia. Am J physiol Gastrointest Liver Physiol. 2008;295(2): G211-218.
11. Sami SS, Ragunath K, Iyer PG. Screening for Barrett's esophagus and esophageal adenocarcinoma: Rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2015;13 (4):623-634.
12. Sikkema M, Kerkhof M, Steyerberg EW, et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: A casecontrol study. Am J Gastroenterol. 2009;104(11):2673-2680.
13. Park JM, Hahm KB. The Korean perspective of Helicobacter pylori infection: Lessons from the Japanese government's policy to prevent gastric cancer. Dig Dis. 2014;32(3):290-294.
14. Sipponen P, Maaroos HI. Chronic gastritis. Scand J Gastroenterol. 2015;50 (6):657-667.
15. Park SH, Kangwan N, Park JM, et al. Non-microbial approach for Helicobacter pylori as faster track to prevent gastric cancer than simple eradication. World J Gastroenterol WJG. 2013;19(47):8986-8995.
16. Keku TO, Dulal S, Deveaux A, et al. The gastrointestinal microbiota and colorectal cancer. Am J Physiol Gastrointest Liver Physiol. 2015;308(5):G351-363.
17. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014;12(10):661-672.
18. Chun KS, Kim EH, Lee S, et al. Chemoprevention of gastrointestinal cancer: The reality and the dream. Gut Liver. 2013;7(2):137-149.
19. Park JM, Han YM, Jeong M, et al. Omega-3 polyunsaturated fatty acids as an angelus custos to rescue patients from NSAID-induced gastroduodenal damage. J Gastroenterol. 2015;50(6):614-625.
20. Williamson KD, Chapman RW. Primary sclerosing cholangitis: A clinical update. Br Med Bull. 2015;114(1):53-64.
21. Singh S, Talwalkar JA. Primary sclerosing cholangitis: Diagnosis, prognosis, and management. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11(8):898-907.
22. Plentz RR, Malek NP. Clinical presentation, risk factors and staging systems of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):245-252.
23. Friman S. Cholangiocarcinoma-current treatment options. Scand J Surg SJS Off Organ Finnish Surg Soc Scand Surg Soc. 2011;100(1):30-34.
24. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol (NY). 2013;10(11):656-665.
25. De Minicis S, Marzioni M, Benedetti A, et al. New insights in hepatocellular carcinoma: From bench to bedside. Ann Transl Med. 2013;1(2):15.
26. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology. 2010;51(5):1820-1832.
27. Caldwell SH, Crespo DM, Kang HS, et al. Obesity and hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1): S97-103.
28. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.
29. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361-371.
30. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol. 2011;12 (8):715-723.
31. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10 (3):181-193.
32. Karin M, Greten FR. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749-759.
33. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitisassociated cancer. Cell. 2004;118(3):285-296.
34. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008;118 (2):560-570.
35. Hahm KB, Im YH, Parks TW, et al. Loss of transforming growth factor beta signaling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut. 2001;49(2):190-198.
36. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA. 2003;100(15):8621-8623.
37. Tang B, Bottinger EP, Jakowlew SB, et al. Transforming growth factor-beta1 is a new formof tumor suppressor with true haploid insufficiency. Nature Medicine. 1998;4 (7):802-807.
38. Engle SJ, Hoying JB, Boivin GP, et al. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res. 1999;59(14):3379-3386.
39. Ota M, Horiguchi M, Fang V, et al. Genetic suppression of inflammation blocks the tumor-promoting effects of TGF-beta in gastric tissue. Cancer Res. 2014;74(9):2642-2651.
40. Parsons R, Myeroff LL, Liu B, et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res. 1995;55(23):5548-5550.
41. Hahm K-B, Lee KM, Kim YB, et al. Conditional loss of TGF-beta signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. Aliment Pharmacol Ther. 2002;16(Suppl 2):115-127.
42. Xu X, Brodie SG, Yang X, et al. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene. 2000;19(15):1868-1874.
43. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271(5247):350-353.
44. Kim BG, Li C, Qiao W, et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature. 2006;441(7096):1015-1019.
45. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6(7):506-520.
46. Matsuoka J, Yashiro M, Doi Y, et al. Hypoxia stimulates the EMT of gastric cancer cells through autocrine TGF? signaling. Plos One. 2013;8(5):e62310.
47. Rees JR, Onwuegbusi BA, Save VE, et al. In vivo and in vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Res. 2006;66(19):9583-9590.
48. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593-601.
49. Dizdaroglu M. Oxidatively induced DNA damage and its repair in cancer. Mutat Res Rev Mutat Res. 2015;763:212-245.
50. Zhu Y, Hu J, Hu Y, et al. Targeting DNA repair pathways: A novel approach to reduce cancer therapeutic resistance. Cancer Treat Rev. 2009;35(7):590-596.
51. Curtin N. Therapeutic potential of drugs to modulate DNA repair in cancer. Expert Opin Ther Targets. 2007;11 (6):783-799.
52. Lyakhovich A, Graifer D. Mitochondrialmediated oxidative stress: Old target for new drugs. Curr Med Chem. 2015;22 (26):3040-3053.
53. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, et al. The causes of cancer revisited: "mitochondrial malignancy" and ROSinduced oncogenic transformation-why mitochondria are targets for cancer therapy. Mol Asp Med. 2010;31(2):145-170.
54. Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12(10):685-698.
55. Milkovic L, Siems W, Siems R, et al. Oxidative stress and antioxidants in carcinogenesis and integrative therapy of cancer. Curr Pharm Des. 2014;20 (42):6529-6542.
56. Iyer AK, Greish K, Seki T, et al. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J Drug Target. 2007;15(7-8):496-506.
57. Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: Initiators, amplifiers or an Achilles' heel? Nat Rev Cancer. 2014;14(11):709-721.
58. Martinon F, Burns K, Tschopp J. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417-426.
59. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821-832.
60. Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(26):4045-4051.
61. Zitvogel L, Kepp O, Galluzzi L, et al. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol. 2012;13(4):343-351.
62. Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19 (1):107-120.
63. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008;14 (5):408-419.
64. Allen IC, TeKippe EM, Woodford RM, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010;207(5):1045-1056.
65. Siegmund B, Lehr HA, Fantuzzi G, et al. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA. 2001;98(23):13249-13254.
66. Bauer C, Duewell P, Mayer C, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010;59 (9):1192-1199.
67. Zaki MH, Lamkanfi M, Kanneganti TD. The Nlrp3 inflammasome: Contributions to intestinal homeostasis. Trends Immunol. 2011;32(4):171-179.
68. Dupaul-Chicoine J, Yeretssian G, Doiron K, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity. 2010;32 (3):367-378.
69. Salcedo R, Worschech A, Cardone M, et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: Role of interleukin 18. J Exp Med. 2010;207(8):1625-1636.
70. Kundu JK, Surh YJ. Inflammation: Gearing the journey to cancer. Mutat Res. 2008;659(1-2):15-30.
71. Kundu JK, Surh Y-J. Emerging avenues linking inflammation and cancer. Free Radic Biol Med. 2012;52(9):2013-2037.
72. Lee HN, Na HK, Surh YJ. Resolution of inflammation as a novel chemopreventive strategy. Semin Immunopathol. 2013;35 (2):151-161.
73. Surh YJ. NF-kappa B and Nrf2 as potential chemopreventive targets of some antiinflammatory and antioxidative phytonutrients with anti-inflammatory and antioxidative activities. Asia Pac J Clin Nutr. 2008;17(Suppl 1):269-272.
74. Tanaka T. Colorectal carcinogenesis: Review of human and experimental animal studies. J Carcinog. 2009;8:5.
75. Gullett NP, Ruhul Amin AR, Bayraktar S, et al. Cancer prevention with natural compounds. Semin Oncol. 2010;37 (3):258-281.
76. Park JM, Lee S, Chung MK, et al. Antioxidative phytoceuticals to ameliorate pancreatitis in animal models: An answer from nature. World J Gastroenterol WJG. 2014;20(44):16570-16581.
77. Park JM, Kwon SH, Han YM, et al. Omega-3 polyunsaturated fatty acids as potential chemopreventive agent for gastrointestinal cancer. J Cancer Prev. 2013;18(3):201-208.
78. Han YM, Park JM, Lee HJ, et al. Shortterm intervention to revert premalignant lesions as strategy to prevent gastrointestinal cancers. J Cancer Prev. 2013;18 (4):289-297.
79. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science. 1997;278(5340):1073-1077.
80. Kangwan N, Park JM, Kim EH, et al. Chemoquiescence for ideal cancer treatment and prevention: Where are we now? J Cancer Prev. 2014;19:89-96.